This study is testing two drugs, VIR-2218 and peginterferon alfa-2a, for people with chronic hepatitis B (HBV) infection. HBV can cause serious liver problems. The study aims to see if these drugs can reduce the amount of hepatitis B surface antigen (HBsAg) in your body. HBsAg is a protein made by the virus. You may be able to join if you are 18-65 years old and have a mild or inactive HBV infection. The study will measure the decline in your HBsAg levels 6 months after all treatment ends to see if the drugs are successful. The current status of this study is unclear, and it plans to enroll up to 50 participants.

Study design

This is an open-label, single-arm study, meaning all participants will receive the same treatment and everyone will know what treatment they are getting. It is a Phase 2a study, which typically looks at the safety and effectiveness of a drug in a small group of people.

What's involved

You will be in the study for over 2 years. You will have blood tests, an eye exam, and liver scans. You will receive VIR-2218 injections under your skin once a month for 6 months.

Compensation

Not stated in the trial record.

Follow-up

The main goal of the study is measured 6 months after all treatment has stopped. There will also be a follow-up to assess the durability of the results 84 weeks after stopping treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.